Aromatic Amines
shared knowledge shared progress
- ABOUT US |
- CONTACT US |
- CAREERS |
- Login
Related News
New data released into our Nitrites in Excipients DatabaseLhasa Limited releases new data to Nitrites in Excipients project users.
14 December 2021
Data release: Lhasa releases new data into its Elemental Impurities Database
08 December 2021
Nitrites in Excipients Data Sharing Initiative: New Data Release
07 October 2021
Related Blog Articles
20 tips for nitrosamine impurity assessmentMany readers will be aware of the risk posed by nitrosamine impurities, as an ongoing pharmaceutical industry hot topic. In July 2021 ANVISA published their guidance for assessment and control of potentially carcinogenic nitrosamines in active pharmaceutical ingredients and drug products. To discuss this topic, we invited knowledgeable speakers from ANVISA, Industry - GSK and Libbs Farmacêutica - and Lhasa to give their perspectives on this topic. This article details the top 20 take away points from the workshop for quick and easy consumption - enjoy!
05 August 2021
The top 5 benefits of data sharing with Vitic [an infographic]
08 April 2021
Working together to address the potential presence of nitrosamine impurities in medications
25 January 2021
Recent News
- Lhasa Limited announces the release of Effiris 2.2 - providing accurate secondary pharmacology predictions for novel compounds
Effiris delivers state-of-the-art secondary pharmacology models, where each model is able to learn from the private data of all pharmaceutical collaborators. As a result, Effiris overcomes one of the main challenges facing model development in drug discovery - accessing and utilising high-quality proprietary data.
Prior to this release, Effiris already offered model building – the ability to build teacher models in Effiris using in-house confidential data, privacy-preserving data sharing – the production of label files which extract knowledge while preserving all confidential aspects of the compounds used, and hybrid model building – collating Effiris member’s confidential dataset labels with the shared knowledge available in Effiris and publicly available data, in order to generate more comprehensive dataset to build a hybrid models.
What can you expect from Effiris 2.2?...
17 January 2022
Recent Blog Articles
Reflecting on 2021 and planning 2022Our CEO, Dr Chris Barber reflects on a successful 12 months for Lhasa and discusses our plans for the year ahead.
20 January 2022
Recent Publications
Nitrosamine Reactivity: A Survey of Reactions and Purge Processes
November 2021Mirabilis
Developing structure-activity relationships for N-nitrosamine activity
November 2021Derek Nexus
Supporting more scientifically driven risk assessments under ICH Q3D
November 2021Elemental Impurities
Recent News
- Lhasa Limited announces the release of Effiris 2.2 - providing accurate secondary pharmacology predictions for novel compounds
Effiris delivers state-of-the-art secondary pharmacology models, where each model is able to learn from the private data of all pharmaceutical collaborators. As a result, Effiris overcomes one of the main challenges facing model development in drug discovery - accessing and utilising high-quality proprietary data.
Prior to this release, Effiris already offered model building – the ability to build teacher models in Effiris using in-house confidential data, privacy-preserving data sharing – the production of label files which extract knowledge while preserving all confidential aspects of the compounds used, and hybrid model building – collating Effiris member’s confidential dataset labels with the shared knowledge available in Effiris and publicly available data, in order to generate more comprehensive dataset to build a hybrid models.
What can you expect from Effiris 2.2?...
17 January 2022
New data released into our Nitrites in Excipients Database
14 December 2021
Data release: Lhasa releases new data into its Elemental Impurities Database
08 December 2021
Recent Blog Articles
- Reflecting on 2021 and planning 2022
Our CEO, Dr Chris Barber reflects on a successful 12 months for Lhasa and discusses our plans for the year ahead.
20 January 2022
Predicting N-nitrosamine carcinogenic potency using structure-activity relationships (SARs)
17 December 2021
How Derek Nexus and Sarah Nexus meet the 5 OECD principles
30 November 2021
© 2022 Lhasa Limited | Registered office: Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS, UK Tel: +44 (0)113 394 6020
VAT number 396 8737 77 | Lhasa Limited is registered as a charity (290866)| Company Registration Number 01765239 (England and Wales).
Apart from the free survey software, we also have access to QuestionPro's free survey templates . We've found many of them useful and powerful to collect insights from various stakeholders of our organization.